Proceedings of the Joint CHSF/HSF/EHSF Pre-WCD Hidradenitis Suppurativa Symposium

The 2015 Hidradenitis Suppurativa (HS) Symposium in Vancouver gathered over 500 participants to discuss advancements in understanding and managing HS, a chronic skin disease. The symposium emphasized the role of hair follicles in HS lesions, the impact of comorbidities, and the necessity for individualized treatment plans. Traditional treatments like antibiotics and surgery were discussed alongside newer methods such as laser therapy and biologics, with adalimumab showing promise in clinical trials. The European guidelines recommended topical clindamycin or tetracycline for mild HS, and for moderate to severe cases, tetracycline or a combination of clindamycin and rifampicin, with adalimumab advised for more severe cases due to its strong evidence and recommendation strength. The symposium underscored the need for further research into HS's epidemiology, pathogenesis, and treatments.